Skip to main content
Top

Open Access 29-01-2025 | Artificial Intelligence | Research

Triaging mammography with artificial intelligence: an implementation study

Authors: Sarah M. Friedewald, Marcin Sieniek, Sunny Jansen, Fereshteh Mahvar, Timo Kohlberger, David Schacht, Sonya Bhole, Dipti Gupta, Shruthi Prabhakara, Scott Mayer McKinney, Stacey Caron, David Melnick, Mozziyar Etemadi, Samantha Winter, Thidanun Saensuksopa, Alejandra Maciel, Luca Speroni, Martha Sevenich, Arnav Agharwal, Rubin Zhang, Gavin Duggan, Shiro Kadowaki, Atilla P. Kiraly, Jie Yang, Basil Mustafa, Yossi Matias, Greg S. Corrado, Daniel Tse, Krish Eswaran, Shravya Shetty

Published in: Breast Cancer Research and Treatment

Login to get access

Abstract

Purpose

Many breast centers are unable to provide immediate results at the time of screening mammography which results in delayed patient care. Implementing artificial intelligence (AI) could identify patients who may have breast cancer and accelerate the time to diagnostic imaging and biopsy diagnosis.

Methods

In this prospective randomized, unblinded, controlled implementation study we enrolled 1000 screening participants between March 2021 and May 2022. The experimental group used an AI system to prioritize a subset of cases for same-visit radiologist evaluation, and same-visit diagnostic workup if necessary. The control group followed the standard of care. The primary operational endpoints were time to additional imaging (TA) and time to biopsy diagnosis (TB).

Results

The final cohort included 463 experimental and 392 control participants. The one-sided Mann-Whitney U test was employed for analysis of TA and TB. In the control group, the TA was 25.6 days [95% CI 22.0–29.9] and TB was 55.9 days [95% CI 45.5–69.6]. In comparison, the experimental group's mean TA was reduced by 25% (6.4 fewer days [one-sided 95% CI > 0.3], p<0.001) and mean TB was reduced by 30% (16.8 fewer days; 95% CI > 5.1], p=0.003). The time reduction was more pronounced for AI-prioritized participants in the experimental group. All participants eventually diagnosed with breast cancer were prioritized by the AI.

Conclusions

Implementing AI prioritization can accelerate care timelines for patients requiring additional workup, while maintaining the efficiency of delayed interpretation for most participants. Reducing diagnostic delays could contribute to improved patient adherence, decreased anxiety and addressing disparities in access to timely care.
Appendix
Available only for authorised users
Literature
3.
go back to reference Daly B, Olopade OI (2015) A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin 65(3):221–38CrossRefPubMed Daly B, Olopade OI (2015) A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin 65(3):221–38CrossRefPubMed
4.
go back to reference Miller-Kleinhenz JM, Collin LJ, Seidel R et al (2021) Racial disparities in diagnostic delay among women with breast cancer. J Am Coll Radiol 18(10):1384–93CrossRefPubMedPubMedCentral Miller-Kleinhenz JM, Collin LJ, Seidel R et al (2021) Racial disparities in diagnostic delay among women with breast cancer. J Am Coll Radiol 18(10):1384–93CrossRefPubMedPubMedCentral
5.
go back to reference Burnside ES, Park JM, Fine JP, Sisney GA (2005) The use of batch reading to improve the performance of screening mammography. AJR Am J Roentgenol 185(3):790–6CrossRefPubMed Burnside ES, Park JM, Fine JP, Sisney GA (2005) The use of batch reading to improve the performance of screening mammography. AJR Am J Roentgenol 185(3):790–6CrossRefPubMed
6.
go back to reference Lindfors KK, O’Connor J, Parker RA (2001) False-positive screening mammograms: effect of immediate versus later work-up on patient stress. Radiology 218(1):247–53CrossRefPubMed Lindfors KK, O’Connor J, Parker RA (2001) False-positive screening mammograms: effect of immediate versus later work-up on patient stress. Radiology 218(1):247–53CrossRefPubMed
7.
go back to reference Dontchos BN, Achibiri J, Mercaldo SF et al (2022) Disparities in same-day diagnostic imaging in breast cancer screening: impact of an immediate-read screening mammography program implemented during the COVID-19 pandemic. AJR Am J Roentgenol 218(2):270–8CrossRefPubMed Dontchos BN, Achibiri J, Mercaldo SF et al (2022) Disparities in same-day diagnostic imaging in breast cancer screening: impact of an immediate-read screening mammography program implemented during the COVID-19 pandemic. AJR Am J Roentgenol 218(2):270–8CrossRefPubMed
8.
go back to reference Oluyemi E (2022) Editorial comment: offering immediate screening mammography interpretation may be an effective way to reduce the racial and ethnic disparity gap in the time to diagnostic follow-up. AJR Am J Roentgenol 218(2):278CrossRefPubMed Oluyemi E (2022) Editorial comment: offering immediate screening mammography interpretation may be an effective way to reduce the racial and ethnic disparity gap in the time to diagnostic follow-up. AJR Am J Roentgenol 218(2):278CrossRefPubMed
9.
go back to reference McKinney SM, Sieniek M, Godbole V et al (2020) International evaluation of an AI system for breast cancer screening. Nature 577(7788):89–94CrossRefPubMed McKinney SM, Sieniek M, Godbole V et al (2020) International evaluation of an AI system for breast cancer screening. Nature 577(7788):89–94CrossRefPubMed
10.
go back to reference Schaffter T, Buist DSM, Lee CI et al (2020) Evaluation of combined artificial intelligence and radiologist assessment to interpret screening mammograms. JAMA Netw Open 3(3):e200265CrossRefPubMedPubMedCentral Schaffter T, Buist DSM, Lee CI et al (2020) Evaluation of combined artificial intelligence and radiologist assessment to interpret screening mammograms. JAMA Netw Open 3(3):e200265CrossRefPubMedPubMedCentral
11.
go back to reference Salim M, Wåhlin E, Dembrower K et al (2020) External evaluation of 3 commercial artificial intelligence algorithms for independent assessment of screening mammograms. JAMA Oncol 6(10):1581–8CrossRefPubMedPubMedCentral Salim M, Wåhlin E, Dembrower K et al (2020) External evaluation of 3 commercial artificial intelligence algorithms for independent assessment of screening mammograms. JAMA Oncol 6(10):1581–8CrossRefPubMedPubMedCentral
12.
go back to reference Rodriguez-Ruiz A, Lång K, Gubern-Merida A et al (2019) Stand-alone artificial intelligence for breast cancer detection in mammography: comparison with 101 radiologists. J Natl Cancer Inst 111(9):916–22CrossRefPubMedPubMedCentral Rodriguez-Ruiz A, Lång K, Gubern-Merida A et al (2019) Stand-alone artificial intelligence for breast cancer detection in mammography: comparison with 101 radiologists. J Natl Cancer Inst 111(9):916–22CrossRefPubMedPubMedCentral
13.
go back to reference Freeman K, Geppert J, Stinton C et al (2021) Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy. BMJ 374:n1872CrossRefPubMedPubMedCentral Freeman K, Geppert J, Stinton C et al (2021) Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy. BMJ 374:n1872CrossRefPubMedPubMedCentral
14.
go back to reference Dembrower K, Crippa A, Colón E, Eklund M, Strand F, ScreenTrustCAD Trial Consortium (2023) Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health 5(10):e703-11CrossRef Dembrower K, Crippa A, Colón E, Eklund M, Strand F, ScreenTrustCAD Trial Consortium (2023) Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health 5(10):e703-11CrossRef
15.
go back to reference Lång K, Josefsson V, Larsson A-M et al (2023) Artificial intelligence-supported screen reading versus standard double reading in the mammography screening with artificial intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol 24(8):936–44CrossRefPubMed Lång K, Josefsson V, Larsson A-M et al (2023) Artificial intelligence-supported screen reading versus standard double reading in the mammography screening with artificial intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol 24(8):936–44CrossRefPubMed
17.
go back to reference Nyante SJ, Abraham L, Ej AB et al (2022) Diagnostic mammography performance across racial and ethnic groups in a national network of community-based breast imaging facilities. Cancer Epidemiol Biomarkers Prev 31(7):1324–1333CrossRefPubMedPubMedCentral Nyante SJ, Abraham L, Ej AB et al (2022) Diagnostic mammography performance across racial and ethnic groups in a national network of community-based breast imaging facilities. Cancer Epidemiol Biomarkers Prev 31(7):1324–1333CrossRefPubMedPubMedCentral
18.
go back to reference Acr. 2013 ACR BI-RADS Atlas: breast imaging reporting and data system (2014) Acr. 2013 ACR BI-RADS Atlas: breast imaging reporting and data system (2014)
19.
go back to reference Efron B, Tibshirani RJ (1994) An introduction to the bootstrap. CRC Press, AmsterdamCrossRef Efron B, Tibshirani RJ (1994) An introduction to the bootstrap. CRC Press, AmsterdamCrossRef
20.
go back to reference Illowsky B, Dean S (2017) Introductory statistics Illowsky B, Dean S (2017) Introductory statistics
21.
go back to reference Lehman CD, Wellman RD, Buist DSM et al (2015) Diagnostic accuracy of digital screening mammography with and without computer-aided detection. JAMA Intern Med 175(11):1828–37CrossRefPubMedPubMedCentral Lehman CD, Wellman RD, Buist DSM et al (2015) Diagnostic accuracy of digital screening mammography with and without computer-aided detection. JAMA Intern Med 175(11):1828–37CrossRefPubMedPubMedCentral
22.
go back to reference Plana D, Shung DL, Grimshaw AA, Saraf A, Sung JJY, Kann BH (2022) Randomized clinical trials of machine learning interventions in health care: a systematic review. JAMA Netw Open 5(9):e2233946CrossRefPubMedPubMedCentral Plana D, Shung DL, Grimshaw AA, Saraf A, Sung JJY, Kann BH (2022) Randomized clinical trials of machine learning interventions in health care: a systematic review. JAMA Netw Open 5(9):e2233946CrossRefPubMedPubMedCentral
Metadata
Title
Triaging mammography with artificial intelligence: an implementation study
Authors
Sarah M. Friedewald
Marcin Sieniek
Sunny Jansen
Fereshteh Mahvar
Timo Kohlberger
David Schacht
Sonya Bhole
Dipti Gupta
Shruthi Prabhakara
Scott Mayer McKinney
Stacey Caron
David Melnick
Mozziyar Etemadi
Samantha Winter
Thidanun Saensuksopa
Alejandra Maciel
Luca Speroni
Martha Sevenich
Arnav Agharwal
Rubin Zhang
Gavin Duggan
Shiro Kadowaki
Atilla P. Kiraly
Jie Yang
Basil Mustafa
Yossi Matias
Greg S. Corrado
Daniel Tse
Krish Eswaran
Shravya Shetty
Publication date
29-01-2025
Publisher
Springer US
Published in
Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-025-07616-7

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now